NCT04901299 - Fulvestrant + Neratinib In Breast Cancer | Biotech Hunter

Timeline

Start Date

July 31, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2025

Conditions

Stage IV (Metastatic) Breast CancerMetastatic Breast CancerER Positive Breast CancerPR-Positive Breast CancerHER2-negative Breast CancerInvasive Breast Cancer

Interventions

DRUG

NERATINIB

Neratinib will be given orally once daily on a continuous daily dosing schedule i.e., no break in dosing. Dosage per protocol

DRUG

FULVESTRANT

Fulvestrant will be given via injection every two weeks for the first 28-day cycle and every four weeks thereafter, dosage per protocol

Trial Locations (2)

37232

Vanderbilt-Ingram Cancer Center, Nashville

02115

Massachusetts General Hospital, Boston